Salute e Benessere
Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
This milestone underscores Shilpa's growing leadership in and , reflecting the company's commitment to advancing patient-centric innovation.
A was conducted across multiple oncology centers in India to compare with conventional ondansetron injections in 240 patients receiving moderately or highly emetogenic chemotherapy.
OERIS™ offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days, eliminating the need for multiple daily doses or oral follow-ups. This innovation enhances patient convenience, improves compliance, and streamlines clinical workflow.
"We are proud to announce the successful completion of this pivotal Phase 3 study," said , . "OERIS™ exemplifies Shilpa's ability to combine scientific innovation with patient-centric design, strengthening our oncology-supportive-care portfolio and our vision to become a global leader in specialty pharmaceuticals."
Shilpa plans to file for regulatory approval with and commercialization through the
pathway in the US and other key markets.
CINV affects up to 70–80% of patients undergoing chemotherapy, representing a market of approximately
USD 375 million . Poorly controlled CINV can lead to treatment discontinuation and reduced quality of life, underscoring need for long-acting therapies such as OERIS™.
is a leading Indian pharmaceutical company specializing in APIs, formulations, and biologics across oncology and specialty segments. For more information, visit www.vbshilpa.com.
Logo - https://mma.prnewswire.com/media/2489785/Shilpa_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/shilpa-medicare-announces-positive-phase-3-results-for-oeris--a-novel-once-weekly-ondansetron-extended-release-injection-for-chemotherapy-induced-nausea-and-vomiting-cinv-302610669.html